GKL-006 Injection

DRUG3 trials

Sponsors

Beijing Gene Key Life Technology Co., Ltd

Conditions

Advanced Pancreatic CancerDuctal Adenocarcinoma of PancreasHepatocellular Carcinoma (HCC)Unresectable Hepatocellular Cancer

Phase 1

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

Active, not recruitingNCT07713290

Beijing Gene Key Life Technology Co., LtdHepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer

Start: 2025-04-03End: 2027-02-28Updated: 2026-07-20

A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

Active, not recruitingNCT07777211

Beijing Gene Key Life Technology Co., LtdAdvanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas

Start: 2025-08-14End: 2027-08-31Target: 52Updated: 2026-08-20

Phase 2

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

RecruitingNCT07209813

Beijing Gene Key Life Technology Co., LtdHepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer

Start: 2025-11-14End: 2027-10-31Target: 48Updated: 2026-08-17